

Test Report

Ordered By

Name Name, PhD, MD.

Collection Date

00/00/0000

Specimen ID

000000

Patient Information

Name Sex Name Name M

Date of Birth

Medical Record Number

00/00/0000 000000000

kidneyintelX.dkd LEVEL



Moderate

In the clinical performance study*, approximately 17% (95% CI 12% to 22%) of patients with Moderate kidneyintelX.dkd Levels experienced progressive decline in kidney function decline within 5 years after their test result.

Signed

Name / Signature

Laboratory Director: Name Name

CLIA Number: 0000000000

Renalytix, 101 6th Avenue, 3rd Floor, Room 324, New York, NY 10013

Report Date

Time

00/00/0000 00:00 AM (UTC)

kidneyintelX.dkd Level	Percent of Patients Experiencing Progressive Decline in Kidney Function (95% CI)	Percent of Patients Experiencing End Stage Kidney Disease (95% CI)
Low	4.6% (2.7% – 7.2%)	0.0%
Moderate	16.7% (12.1% – 22.2%)	3.1% (1.2% – 6.2%)
High	41.8% (28.7% – 55.9%)	18.2% (9.1% – 30.9%)

*Based on clinical performance study results in the kidneyintelX.dkd Product Technical Sheet. The kidneyintelX.dkd Levels (Low, Moderate, and High) correlate with the probability of progressive decline in kidney function.

To receive a kidneyintelX.dkd Product Technical Sheet, contact Client Services at (888) 203-2725 or at clientservices@renalytix.com.

kidneyintelX.com



renalytix™

kidneyintelX.dkd Product Technical Sheet (printed copy) is promptly provided at no cost upon request.